FDA Safety Labeling Change Order for ADZYNMA

The FDA issued a safety labeling change order requiring Takeda Pharmaceuticals to update the prescribing information for ADZYNMA. The manufacturer must submit labeling supplements with the required changes by the specified deadline.

What changed: FDA ordered safety labeling changes for ADZYNMA to update safety information in the prescribing information.

Why it matters: Updated safety information may include new warnings, precautions, or adverse reactions that impact risk-benefit assessment and signal management.

Practical implication: Review the specific labeling changes required by the FDA order and update internal safety documents and signal evaluation for ADZYNMA accordingly.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.